Clinical Studies, Regulatory Clearance, Financial Results, and Approvals - Research Report on Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, and Novartis

Thu Oct 31, 2013 9:01am EDT

* Reuters is not responsible for the content in this press release.

Clinical Studies, Regulatory Clearance, Financial Results, and Approvals - Research Report on Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, and Novartis

PR Newswire

NEW YORK, October 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), and Novartis AG (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On October 28, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and Alder Biopharmaceuticals announced the presentation of efficacy and safety data from a Phase IIb dose-ranging study of subcutaneous (SC) clazakizumab in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Bristol-Myers Squibb stated that Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine rather than its receptor. The Company informed that all clazakizumab treatment arms, both as monotherapy as well as in combination with methotrexate (MTX), met the primary endpoint of ACR20 response at 12 weeks, compared to MTX alone. Bristol-Myers Squibb stated that it has exclusive worldwide rights to develop and commercialize clazakizumab for all indications outside of cancer under a collaboration agreement with its discoverer, Alder Biopharmaceuticals. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/81a9_BMY]

Merck & Co. Inc. Research Report

On October 28, 2013, Merck & Co. Inc. (Merck & Co.) reported its Q3 2013 financial results. Total sales decreased c.4% YoY to $11.0 billion. Net income attributable to Merck & Co. was reported at $1.1 billion or $0.38 per diluted share for Q3 2013, compared to $1.7 billion or $0.56 per diluted share in Q3 2012. Chairman and CEO Kenneth C. Frazier said, "This quarter we delivered solid financial results, with strong contributions from our vaccine, immunology and HIV businesses, and effective cost management. We are encouraged that our combination hepatitis C regimen has joined our anti-PD-1 immunotherapy in being designated as a 'breakthrough therapy' by the FDA." For full-year 2013, the Company targets to achieve an EPS of $1.61 to $1.79. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]

Johnson & Johnson Research Report

On October 28, 2013, Ethicon Endo-Surgery, Inc. (Ethicon), a Johnson & Johnson (Johnson & Johnson) Company, announced that HARMONIC ACE+ 7 Shears with Advanced Hemostasis (HARMONIC ACE +7) has received 510(k) clearance from the US FDA. According to the Company, HARMONIC ACE+ 7 is the first ultrasonic surgical device indicated to seal vessels up to and including 7mm, while also delivering on the HARMONIC promise of precision and multi-functionality. The Company stated that the HARMONIC ACE+ 7 represents the latest evolution in the HARMONIC legacy of innovation and leverages the proprietary Adaptive Tissue Technology, which enables the system to actively sense and adapt to changing tissue conditions and intelligently deliver energy resulting in improved performance with superior precision. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

AbbVie Inc. Research Report

On October 25, 2013, AbbVie Inc. (AbbVie) reported its Q3 2013 financial results. Net sales increased 3.3% YoY to $4.7 billion. Net earnings were $964.0 million or $0.60 per diluted share in Q3 2013, compared to $1.6 billion or $1.01 per diluted share in Q3 2012. Chairman and CEO Richard A. Gonzalez said, "Our third-quarter performance demonstrates the strength and durability of our product portfolio and the continued execution of our key strategic priorities as an independent biopharmaceutical company. Our mid- to late-stage pipeline contains a number of potentially significant opportunities, and we look forward to a series of milestones across our pipeline in the coming months." For full-year 2013, the Company revised its diluted EPS guidance to $2.54 to $2.56. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]

Novartis AG Research Report

On October 23, 2013, Novartis AG (Novartis) reported that Alcon, the second largest division of the Company, has received positive recommendation from National Institute for Health and Care Excellence (NICE) for Jetrea (ocriplasmin) as a clinically and cost-effective treatment option for eligible patients suffering from vitreomacular traction including when associated with macular hole. The Company informed that with this final NICE guidance, Jetrea is now recommended for use within the National Health Service (NHS) in England and Wales as the first and only pharmacological treatment for this sight-threatening eye condition. Stuart Raetzman, Area President Europe, Middle East and Africa, Alcon, commented, "We are very pleased by the NICE decision, as Jetrea® represents a breakthrough treatment option for patients in the UK, which is now recommended for use in the NHS." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.